ReviewDiscover oncology2025
Chronic stress-related neuroendocrine mediators and ovarian cancer.
Review in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Neuron-tumor crosstalk in cancer: molecular mechanisms and translational advances.Molecular cancer · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Ovarian cancer (OC), as one of the three major gynecological tumors, has been known as the "silent killer". It is characterized by high mortality, high recurrence rate, and frequent drug resistance. Chronic stress has been increasingly recognized as a potential contributor to ovarian cancer progression through dysregulation of neuroendocrine pathways, particularly via the prolonged activation of the hypothalamic-pituitary-adrenal (HPA) axis and the sympathetic nervous system (SNS). Key mediators, including glucocorticoids (GCs), catecholamines (epinephrine (E), norepinephrine (NE), and dopamine (DA)), and other neuroendocrine factors, contribute to tumor progression by modulating cell proliferation, metastasis, angiogenesis, chemoresistance, and tumor immune microenvironment. This review summarizes current evidence on the role of neuroendocrine mediators in ovarian cancer progression, highlighting molecular mechanisms, clinical and preclinical findings, and potential therapeutic strategies. Understanding neuroendocrine-ovarian cancer crosstalk may provide novel insights into ovarian cancer progression and inform combinatorial therapies targeting stress-mediated tumorigenesis.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.